Stem cells for heart failure
Friday, 06 June, 2008
Mesoblast (ASX: MSB) will soon launch phase II trials into congestive heart failure, the company said.
The trials will be conducted by its US-based sister company Angioblast Systems.
The US FDA recently granted the companies permission to perform clinical trials using its adult stem cell-based treatment.
45 clients suffering from congestive heart failure will be given allogeneic stem cells, while 15 will be given a placebo.
The stem cells will be injected directly into the patients' hearts through a cardiac catheter.
In pilot trials conducted in Australia, a similar injection method using the patients' own cells was shown to improve heart muscle function and reduce the risk of heart failure. Mesoblast said using healthy stem cells will improve the results even further.
SEQ koala population carries immunity to retrovirus
Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...
RSV immunisation program for babies slashes hospital stays
An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...
A targeted treatment option for psoriasis
New research from MedUni Vienna paves the way for the development of a therapy that not only...
